Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2004

01-10-2004 | Article

Ischaemic preconditioning does not protect the heart in obese and lean animal models of Type 2 diabetes

Authors: S. B. Kristiansen, B. Løfgren, N. B. Støttrup, D. Khatir, J. E. Nielsen-Kudsk, T. T. Nielsen, H. E. Bøtker, A. Flyvbjerg

Published in: Diabetologia | Issue 10/2004

Login to get access

Abstract

Aims/hypothesis

The prevalence of Type 2 diabetes mellitus is increasing worldwide with obese diabetic patients constituting the majority of this population. Type 2 diabetes is associated with increased morbidity and mortality after acute myocardial infarction. Previous experimental studies of ischaemia-reperfusion tolerance in diabetes have only been performed in animal models of Type 1 diabetes mellitus, yielding conflicting data. The aim of the present study was to characterise and compare the tolerance to ischaemia and effects of ischaemic preconditioning (IPC) in hearts from obese Zucker diabetic fatty (ZDF) and lean Goto-Kakizaki (GK) Type 2 diabetic rats, using non-obese Zucker and Wistar rats as respective controls.

Methods

The two rat strains were divided into 8 groups. The ZDF study (n=47) consisted of: Control −IPC, Control +IPC, ZDF −IPC and ZDF +IPC. The GK study (n=38) consisted of: Control −IPC, Control +IPC, GK −IPC and GK +IPC. Hearts, which were studied in a Langendorff preparation perfused with Krebs-Henseleit buffer, were subjected or not to IPC (+IPC, −IPC) before 50 minutes of regional ischaemia and 120 minutes reperfusion.

Results

Ischaemic reperfusion injury was smaller in obese (p<0.05) and lean (p<0.05) Type 2 diabetic animals than in their respective control animals. IPC reduced ischaemic reperfusion injury during reperfusion in non-diabetic control rats (p<0.01), but failed to protect hearts from both diabetic animal models. Post-ischaemic haemodynamic recovery was impaired in the ZDF rats compared to both control and GK rats (p<0.05).

Conclusions/interpretation

Ischaemic preconditioning does not protect hearts from obese or lean Type 2 diabetic animals. However, the susceptibility of the Type 2 diabetic myocardium to ischaemic damage is lower than in non-diabetic hearts. The method described here could be used as a tool to study the pathogenesis of increased cardiovascular morbidity and mortality in Type 2 diabetes.
Literature
1.
King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431PubMed
2.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed
3.
Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787CrossRefPubMed
4.
Feuvray D, Lopaschuk GD (1997) Diabetes mellitus and the cardiovascular system. Cardiovasc Res 34:1–2CrossRefPubMed
5.
Clark JB, Palmer CJ, Shaw WN (1983) The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 173:68–75PubMed
6.
Peterson RG, Shaw WN, Neel M-A, Little LA, Eichberg J (1990) Zucker diabetic fatty rats as a model for non-insulin-dependent diabetes mellitus. ILAR News 32:16–19
7.
Goto Y, Kakizaki M, Masaki N (1975) Spontaneous diabetes produced by selective breeding of normal Wistar rats. Proc Japan Acad 51:80–85
8.
Movassat J, Saulnier C, Portha B (1995) Beta-cell mass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent diabetes mellitus. Diabetes Metab 21:365–370
9.
Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW (1993) Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88:1273–1278PubMed
10.
Tani M, Neely JR (1988) Hearts from diabetic rats are more resistant to in vitro ischemia: possible role of altered Ca2+ metabolism. Circ Res 62:931–940PubMed
11.
Forrat R, Sebbag L, Wiernsperger N, Guidollet J, Renaud S, De Lorgeril M (1993) Acute myocardial infarction in dogs with experimental diabetes. Cardiovasc Res 27:1908–1912PubMed
12.
Feuvray D, Idell-Wenger JA, Neely JR (1979) Effects of ischemia on rat myocardial function and metabolism in diabetes. Circ Res 44:322–329PubMed
13.
Vogel WM, Apstein CS (1988) Effects of alloxan-induced diabetes on ischemia-reperfusion injury in rabbit hearts. Circ Res 62:975–982PubMed
14.
Wang P, Chatham JC (2004) Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function following ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metab 286:E725–E736CrossRefPubMed
15.
Gotzsche O (1982) Lack of cardiotoxic effect of isoproterenol in streptozotocin diabetic rats. A morphometric study of isoproterenol induced fibrosis. Virchows Arch A Pathol Anat Histol 397:83–91PubMed
16.
Tosaki A, Engelman DT, Engelman RM, Das DK (1996) The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 31:526–536CrossRefPubMed
17.
Bouchard JF, Lamontagne D (1998) Protection afforded by preconditioning to the diabetic heart against ischaemic injury. Cardiovasc Res 37:82–90CrossRefPubMed
18.
Ghosh S, Standen NB, Galinianes M (2001) Failure to precondition pathological human myocardium. J Am Coll Cardiol 37:711–718CrossRefPubMed
19.
Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH (1997) Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96:29–32PubMed
20.
Ebel D, Mullenheim J, Frassdorf J et al. (2003) Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo. Pflugers Arch 446:175–182PubMed
21.
Marfella R, Di Filippo C, Esposito K et al. (2004) Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 53:454–462PubMed
22.
Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC (1998) Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 275:H721–H725PubMed
23.
Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC (2000) Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 278:H1218–H1224PubMed
24.
Ishihara M, Inoue I, Kawagoe T et al. (2001) Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 38:1007–1011CrossRefPubMed
Metadata
Title
Ischaemic preconditioning does not protect the heart in obese and lean animal models of Type 2 diabetes
Authors
S. B. Kristiansen
B. Løfgren
N. B. Støttrup
D. Khatir
J. E. Nielsen-Kudsk
T. T. Nielsen
H. E. Bøtker
A. Flyvbjerg
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1514-4

Other articles of this Issue 10/2004

Diabetologia 10/2004 Go to the issue

Article

High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in Type 1 diabetic pregnancies

Observation

Sustained glucose-stimulated insulin secretion in mouse islets is not culture-dependent

Article

Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects

Short Communication

The complexity of non-enzymatic glycation product sets of human globins

For Debate

Animal models have little to teach us about Type 1 diabetes: 2. In opposition to this proposal

Article

Cellular basis of diabetic nephropathy: III. In vitro GLUT1 mRNA expression and risk of diabetic nephropathy in Type 1 diabetic patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits